Skip to main content
Erschienen in: Endocrine 2/2012

01.10.2012 | Original Article

Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency

verfasst von: Linman Li, Wei Ren, Jinchao Li, Jingjing Liu, Lingli Wang, Xiaoya Zheng, Dezhen Liu, Sufang Li, Rhonda Souvenir, Jiping Tang

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Adult Growth Hormone Deficiency (AGHD) is correlated to many adverse effects on metabolism and increased cardiovascular risk. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that promotes IGF-I availability in vascular tissues in recent study, and PAPP-A levels have been proposed as an early predictor of cardiac events. The aim of our study was to compare PAPP-A levels in AGHD patients with that of healthy adult subjects to determine if there is a relationship between serum PAPP-A and glucose and lipid metabolism. Twenty AGHD patients and 20 healthy, age-matched and weight-matched persons were chosen for the study. Their weight, height, blood pressure, body mass index (BMI), body fat percentage, waist and hip circumference, and waist–hips ratio were assessed. An oral glucose tolerance test was performed and venous blood was collected from the each patient’s cubital vein for biochemical analysis. Serum PAPP-A level in AGHD patients was significantly higher than that of the control group [(7.62 ± 1.62 vs. 6.54 ± 1.31) p < 0.05], and PAPP-A was positively correlated to age, BMI, waist circumference and so on. After adjusting for the waist circumference, waist–hip ratio, 2 h postprandial blood glucose, triglycerides, the serum PAPP-A in AGHD patients was positively correlated to the BMI (r = 0.728, p < 0.05) and fasting insulin (r = 0.433, p < 0.05). In a multiple step-wise regression analysis, BMI, 2 h postprandial glucose, fasting insulin, HOMA-IR were independently associated with serum PAPP-A in AGHD patients. The increase in serum PAPP-A levels is associated with abnormal glucose metabolism and increased risk of atherosclerosis in AGHD patients.
Literatur
1.
Zurück zum Zitat H.L. Fideleff, A. Chervin, A. Giaccio, P. Sobrado, R. Barmat et al., Adult growth hormone deficiency. Metabolic alterations and evaluation of different risk groups. Medicina (B Aires) 64, 13–19 (2004) H.L. Fideleff, A. Chervin, A. Giaccio, P. Sobrado, R. Barmat et al., Adult growth hormone deficiency. Metabolic alterations and evaluation of different risk groups. Medicina (B Aires) 64, 13–19 (2004)
2.
Zurück zum Zitat A. Sanmartí, A. Lucas, F. Hawkins, S.M. Webb, A. Ulied, Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (observational GH deficiency in adults) group. Eur. J. Endocrinol. 141, 481–489 (1999)PubMedCrossRef A. Sanmartí, A. Lucas, F. Hawkins, S.M. Webb, A. Ulied, Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status. Collaborative ODA (observational GH deficiency in adults) group. Eur. J. Endocrinol. 141, 481–489 (1999)PubMedCrossRef
3.
Zurück zum Zitat B. Bülow, L. Hagmar, C.H. Nordström, Z. Mikoczy, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46, 75–81 (1997)CrossRef B. Bülow, L. Hagmar, C.H. Nordström, Z. Mikoczy, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 46, 75–81 (1997)CrossRef
4.
Zurück zum Zitat J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton et al., Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001)PubMedCrossRef J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton et al., Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001)PubMedCrossRef
5.
Zurück zum Zitat J. Svensson, B.-A. Bengtsson, T. Rosén, A. Odén, G. Johannsson et al., Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89, 3306–3312 (2004)PubMedCrossRef J. Svensson, B.-A. Bengtsson, T. Rosén, A. Odén, G. Johannsson et al., Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 89, 3306–3312 (2004)PubMedCrossRef
6.
Zurück zum Zitat M. Gola, S. Bonadonna, M. Doga, G. Mazziotti, A. Giustina, Cardiovascular risk in aging and obesity: is there a role for GH. J. Endocrinol. Invest. 28, 759–767 (2005)PubMed M. Gola, S. Bonadonna, M. Doga, G. Mazziotti, A. Giustina, Cardiovascular risk in aging and obesity: is there a role for GH. J. Endocrinol. Invest. 28, 759–767 (2005)PubMed
7.
Zurück zum Zitat B. Bulow, L. Hangmar, J. Eskilsson, E.M. Erfurth, Hypopituitary females have a high incidence of cardiovascular morbidity and increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85, 574–584 (2000)PubMedCrossRef B. Bulow, L. Hangmar, J. Eskilsson, E.M. Erfurth, Hypopituitary females have a high incidence of cardiovascular morbidity and increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85, 574–584 (2000)PubMedCrossRef
8.
Zurück zum Zitat A. Colao, C. Di Somma, S. Spiezia, S. Savastano, F. Rota et al., Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 3416–3424 (2008)PubMedCrossRef A. Colao, C. Di Somma, S. Spiezia, S. Savastano, F. Rota et al., Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 3416–3424 (2008)PubMedCrossRef
9.
Zurück zum Zitat P.H. Su, S.F. Yang, J.S. Yu, S.J. Chen, J.Y. Chen, Study of the leptin levels and its gene polymorphisms in patients with idiopathic short stature and growth hormone deficiency. Endocrine (2012 in press) P.H. Su, S.F. Yang, J.S. Yu, S.J. Chen, J.Y. Chen, Study of the leptin levels and its gene polymorphisms in patients with idiopathic short stature and growth hormone deficiency. Endocrine (2012 in press)
10.
Zurück zum Zitat A. Colao, C. Di Somma, M.C. Savanelli, M. De Leo, G. Lombardi, Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm. IGF Res. 16(Suppl A), S41–S48 (2006)PubMedCrossRef A. Colao, C. Di Somma, M.C. Savanelli, M. De Leo, G. Lombardi, Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm. IGF Res. 16(Suppl A), S41–S48 (2006)PubMedCrossRef
11.
Zurück zum Zitat T. Mueller, B. Dieplinger, W. Poelz, M. Haltmayer, Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. Clin. Chem. 52, 1096–1103 (2006)PubMedCrossRef T. Mueller, B. Dieplinger, W. Poelz, M. Haltmayer, Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. Clin. Chem. 52, 1096–1103 (2006)PubMedCrossRef
12.
Zurück zum Zitat J.L. Beaudeux, L. Burc, F. Imbert-Bismut, P. Giral, M. Bernard et al., Serum/plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in a symptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 23, e7–e10 (2003)PubMedCrossRef J.L. Beaudeux, L. Burc, F. Imbert-Bismut, P. Giral, M. Bernard et al., Serum/plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in a symptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 23, e7–e10 (2003)PubMedCrossRef
13.
Zurück zum Zitat C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons et al., Pregnancy associated plasma protein-A levels in patients with acute coronary syndromes:comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45, 229–237 (2005)PubMedCrossRef C. Heeschen, S. Dimmeler, C.W. Hamm, S. Fichtlscherer, M.L. Simoons et al., Pregnancy associated plasma protein-A levels in patients with acute coronary syndromes:comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 45, 229–237 (2005)PubMedCrossRef
14.
Zurück zum Zitat M. Doga, S. Bonadonna, M. Gola, G. Mazziotti, A. Giustina, Growth hormone deficiency in the adult. Pituitary 9, 305–311 (2006)PubMedCrossRef M. Doga, S. Bonadonna, M. Gola, G. Mazziotti, A. Giustina, Growth hormone deficiency in the adult. Pituitary 9, 305–311 (2006)PubMedCrossRef
15.
Zurück zum Zitat J.B. Lawrence, C. Oxvig, M.T. Overgaard, L. Sottrup-Jensen, G.J. Gleich et al., The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA 96, 3149–3153 (1999)PubMedCrossRef J.B. Lawrence, C. Oxvig, M.T. Overgaard, L. Sottrup-Jensen, G.J. Gleich et al., The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA 96, 3149–3153 (1999)PubMedCrossRef
16.
Zurück zum Zitat M.T. Overgaard, C. Oxvig, M. Christiansen, J.B. Lawrence, C.A. Conover et al., Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonproductive tissues. Biol. Reprod. 61, 1083–1089 (1999)PubMedCrossRef M.T. Overgaard, C. Oxvig, M. Christiansen, J.B. Lawrence, C.A. Conover et al., Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonproductive tissues. Biol. Reprod. 61, 1083–1089 (1999)PubMedCrossRef
17.
Zurück zum Zitat G.A. Bayes, C.A. Conover, M.T. Overgaard, K.R. Bailey, M. Christiansen et al., Pregnancy-associated plasm a protein-A as a marker of acute coronary syndromes. N. Engl. J. Med. 345, 1022–1029 (2001)CrossRef G.A. Bayes, C.A. Conover, M.T. Overgaard, K.R. Bailey, M. Christiansen et al., Pregnancy-associated plasm a protein-A as a marker of acute coronary syndromes. N. Engl. J. Med. 345, 1022–1029 (2001)CrossRef
18.
Zurück zum Zitat H.B. Boldt, M.T. Overgaard, L.S. Laursen, K. Weyer, L. Sottrup-Jensen et al., Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem J 358, 267–359 (2001)CrossRef H.B. Boldt, M.T. Overgaard, L.S. Laursen, K. Weyer, L. Sottrup-Jensen et al., Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem J 358, 267–359 (2001)CrossRef
19.
Zurück zum Zitat C. Joaquin, E. Aguilera, M.L. Granada, M.C. Pastor, I. Salinas et al., Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 158, 483–490 (2008)PubMedCrossRef C. Joaquin, E. Aguilera, M.L. Granada, M.C. Pastor, I. Salinas et al., Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol. 158, 483–490 (2008)PubMedCrossRef
20.
Zurück zum Zitat D. González-Duarte, A. Madrazo-Atutxa, A. Soto-Moreno, A. Leal-Cerro, Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency. Pituitary (2012 in press) D. González-Duarte, A. Madrazo-Atutxa, A. Soto-Moreno, A. Leal-Cerro, Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency. Pituitary (2012 in press)
21.
Zurück zum Zitat C.A. Conover, L.K. Bale, S.C. Harrington, Z.T. Resch, M.T. Overgaard, C. Oxvig, Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol. Am. J. Physiol. Cell Physiol. 290, C183–C188 (2006)PubMedCrossRef C.A. Conover, L.K. Bale, S.C. Harrington, Z.T. Resch, M.T. Overgaard, C. Oxvig, Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol. Am. J. Physiol. Cell Physiol. 290, C183–C188 (2006)PubMedCrossRef
22.
Zurück zum Zitat A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12, 163–172 (2000)PubMedCrossRef A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12, 163–172 (2000)PubMedCrossRef
23.
Zurück zum Zitat R. Sode-Carlsen, S. Farholt, K.F. Rabben, J. Bollerslev, T. Schreiner et al., Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 41, 191–199 (2012)PubMedCrossRef R. Sode-Carlsen, S. Farholt, K.F. Rabben, J. Bollerslev, T. Schreiner et al., Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 41, 191–199 (2012)PubMedCrossRef
24.
Zurück zum Zitat J.R. Sowers, Obesity as a cardiovascular risk factor. Am. J. Med. 115, 37–41 (2003)CrossRef J.R. Sowers, Obesity as a cardiovascular risk factor. Am. J. Med. 115, 37–41 (2003)CrossRef
25.
Zurück zum Zitat J.O. Johansson, J. Fowelin, K. Landin, I. Lager, B.A. Bengtsson, Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126–1129 (1995)PubMedCrossRef J.O. Johansson, J. Fowelin, K. Landin, I. Lager, B.A. Bengtsson, Growth hormone-deficient adults are insulin-resistant. Metabolism 44, 1126–1129 (1995)PubMedCrossRef
26.
Zurück zum Zitat R. Arumugam, D. Fleenor, M. Freemark, Effects of lactogen resistance and GH deficiency on mouse metabolism: pancreatic hormones, adipocytokines, and expression of adiponectin and insulin receptors. Endocrine 32, 182–191 (2007)PubMedCrossRef R. Arumugam, D. Fleenor, M. Freemark, Effects of lactogen resistance and GH deficiency on mouse metabolism: pancreatic hormones, adipocytokines, and expression of adiponectin and insulin receptors. Endocrine 32, 182–191 (2007)PubMedCrossRef
27.
Zurück zum Zitat J. Ukropec, A. Penesová, M. Skopková, M. Pura, M. Vlcek et al., Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J. Clin. Endocrinol. Metab. 93, 2255–2262 (2008)PubMedCrossRef J. Ukropec, A. Penesová, M. Skopková, M. Pura, M. Vlcek et al., Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J. Clin. Endocrinol. Metab. 93, 2255–2262 (2008)PubMedCrossRef
28.
Zurück zum Zitat N. Vahl, I. Klausen, J.S. Christiansen, J.O. Jørgensen, Growth hormone status is an independent determinant of serum levels of cholesterol and triglycerides in healthy subjects. Clin. Endocrinol. 51, 309–316 (1999)CrossRef N. Vahl, I. Klausen, J.S. Christiansen, J.O. Jørgensen, Growth hormone status is an independent determinant of serum levels of cholesterol and triglycerides in healthy subjects. Clin. Endocrinol. 51, 309–316 (1999)CrossRef
29.
Zurück zum Zitat R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson et al., Determinants of cardiovascular risk in 2,589 hypopituitary growth hormone-deficient adults. Eur. J. Endocrinol. 155, 79–90 (2006)PubMedCrossRef R. Abs, U. Feldt-Rasmussen, A.F. Mattsson, J.P. Monson, B.A. Bengtsson et al., Determinants of cardiovascular risk in 2,589 hypopituitary growth hormone-deficient adults. Eur. J. Endocrinol. 155, 79–90 (2006)PubMedCrossRef
30.
Zurück zum Zitat Y. Momiyama, R. Ohmori, Z.A. Fayad, T. Kihara, N. Tanaka et al., Association between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. J. Atheroscler. Thromb. 17, 460–467 (2010)PubMedCrossRef Y. Momiyama, R. Ohmori, Z.A. Fayad, T. Kihara, N. Tanaka et al., Association between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. J. Atheroscler. Thromb. 17, 460–467 (2010)PubMedCrossRef
31.
Zurück zum Zitat A. Juul, T. Scheike, M. Davidsen, J. Gyllenborg, T. Jørgensen, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106, 939–944 (2002)PubMedCrossRef A. Juul, T. Scheike, M. Davidsen, J. Gyllenborg, T. Jørgensen, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106, 939–944 (2002)PubMedCrossRef
32.
Zurück zum Zitat K.K. Miller, T. Wexler, P. Fazeli, L. Gunnell, G.J. Graham et al., Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J. Clin. Endocrinol. Metab. 95, 567–577 (2010)PubMedCrossRef K.K. Miller, T. Wexler, P. Fazeli, L. Gunnell, G.J. Graham et al., Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J. Clin. Endocrinol. Metab. 95, 567–577 (2010)PubMedCrossRef
33.
Zurück zum Zitat C. Beauregard, A.L. Utz, A.E. Schaub, L. Nachtigall, B.M. Biller et al., Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2063–2071 (2008)PubMedCrossRef C. Beauregard, A.L. Utz, A.E. Schaub, L. Nachtigall, B.M. Biller et al., Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2063–2071 (2008)PubMedCrossRef
34.
Zurück zum Zitat K.A. Al-Shoumer, K. Ali, V. Anyaoku, R. Niththyananthan, D.G. Johnston, Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin. Endocrinol. (Oxf) 45, 171–178 (1996)CrossRef K.A. Al-Shoumer, K. Ali, V. Anyaoku, R. Niththyananthan, D.G. Johnston, Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism. Clin. Endocrinol. (Oxf) 45, 171–178 (1996)CrossRef
35.
Zurück zum Zitat Y. Kato, H.Y. Hu, M. Sohmiya, Short-term treatment with different doses of human growth hormone in adult patients with growth hormone deficiency. Endocr. J. 43, 177–183 (1996)PubMedCrossRef Y. Kato, H.Y. Hu, M. Sohmiya, Short-term treatment with different doses of human growth hormone in adult patients with growth hormone deficiency. Endocr. J. 43, 177–183 (1996)PubMedCrossRef
36.
Zurück zum Zitat E. Kousta, A. Chrisoulidou, N.J. Lawrence, V. Anyaoku, K.A. Al-Shoumer et al., The effects of growth hormone replacement therapy on over night metabolic fuels in hypopituitary patients. Clin. Endocrinol. (Oxf) 52, 17–24 (2000)CrossRef E. Kousta, A. Chrisoulidou, N.J. Lawrence, V. Anyaoku, K.A. Al-Shoumer et al., The effects of growth hormone replacement therapy on over night metabolic fuels in hypopituitary patients. Clin. Endocrinol. (Oxf) 52, 17–24 (2000)CrossRef
Metadaten
Titel
Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency
verfasst von
Linman Li
Wei Ren
Jinchao Li
Jingjing Liu
Lingli Wang
Xiaoya Zheng
Dezhen Liu
Sufang Li
Rhonda Souvenir
Jiping Tang
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9697-9

Weitere Artikel der Ausgabe 2/2012

Endocrine 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.